Evaluation of Automatic Signal Detection of In Situ Hybridization for Detecting HPV DNA in Cervical Tissue Derived from Patients with Cervical Intraepithelial Neoplasia
by
, , , , , and
Marcin Przybylski
1
,
Sonja Millert-Kalińska
1,2
,
Mateusz de Mezer
3,
Monika Krzyżaniak
4,
Paweł Kurzawa
4,
Jakub Żurawski
3,
Robert Jach
5
and
Dominik Pruski
1,6,* 1
Department of Obstetrics and Gynaecology, District Public Hospital, 60-479 Poznan, Poland
2
Doctoral School, Poznan University of Medical Sciences, 60-812 Poznan, Poland
3
Department of Immunobiology, Poznan University of Medical Sciences, 60-812 Poznan, Poland
4
Department of Pathomorphology, University Clinical Hospital in Poznan, 60-572 Poznan, Poland
5
Department of Gynecological Endocrinology, Jagiellonian University Medical College, 31-008 Kraków, Poland
6
Gynecology Specialised Practise, 60-408 Poznan, Poland
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(20), 3485; https://doi.org/10.3390/cancers16203485
Submission received: 11 September 2024
/
Revised: 2 October 2024
/
Accepted: 10 October 2024
/
Published: 15 October 2024
(This article belongs to the Special Issue Virus-Associated Cancers)
Simple Summary
Cervical cancer is the fourth most common cancer in women worldwide, with HPV being a prevalent cause. Recent automated signal detection methods in ISH assays have shown promise for detecting HPV DNA in cervical tissue. This study compared an ISH probe (Inform HPV II and III) to PCR assays in cervical tissue samples with varying degrees of cervical intraepithelial neoplasia (CIN) and normal cervix tissue. Findings indicated a significant association between ISH III levels and HPV outcomes; patients with positive outcomes had lower ISH III levels (MD = −7961.82, p = 0.005). However, automatic signal detection for ISH is limited in cervical tissue, making genotyping-based HPV testing more effective, as it allows for larger sample collection. ISH results should be interpreted alongside clinical history and morphology.
Abstract
Background: Cervical cancer is fourth the most common cancer in women worldwide. Due to the prevalence of human papillomavirus (HPV) in the population (80–90%), scientists are likely to discover even more associations of this pathogen with other diseases in the future. In recent years, In Situ Hybridization (ISH) assays that use automated signal-detecting methods in formalin-fixed, paraffin-embedded (FFPE) cervical tissue, such as the enzyme-categorized signal-detecting system, have shown a higher sensitivity. Objectives and Methods: To evaluate automatic signal detection of ISH assay for detecting HPV DNA, we compared the ability of an ISH probe, Inform HPV II and III (Ventana Medical Systems, Tucson, AZ), to that of PCR assays to detect HPV DNA in cervical tissue specimens with cervical intraepithelial neoplasia (CIN; CIN 1, 28 cases; CIN 2, 22 cases; and CIN 3, 20 cases) and normal cervix (2 cases). Results: Our findings showed a significant relation was confirmed between ISH III level and HPV outcome (positive/negative). Patients with positive HPV outcomes had significantly lower ISH III levels, MD = −7961.82 CI95 [−17,230.00; −199.21], p = 0.005. Conclusions: Automatic signal detection of ISH assay is not particularly applicable to cervical tissue material. A more useful method of confirming the presence of HPV in the cervix is the HPV test with genotyping, as it allows for collecting a larger amount of material from the cervical disc and canal. The interpretation of a positive or negative ISH test must be guided in the context of clinical history and morphology.
Keywords:
automatic signal detection; automatic response field; FFPE; ISH; HPV DNA; CIN; SIL; in situ Hybridization
